Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39.3M | $41.4M | $42.0M | $46.9M | $42.2M | $49.1M | $52.3M | $50.2M | $40.9M | $38.5M |
| Revenue growth | — | 5.4% | 1.4% | 11.7% | -10.1% | 16.3% | 6.6% | -3.9% | -18.6% | -5.8% |
| Gross profit | $23.7M | $26.4M | $26.3M | $29.5M | $25.5M | $30.9M | $32.2M | $30.0M | $24.1M | $22.0M |
| Gross margin | 60.3% | 63.7% | 62.6% | 62.8% | 60.6% | 63.0% | 61.6% | 59.8% | 59.0% | 57.1% |
| Operating income | $16.2M | $19.0M | $18.7M | $17.6M | $13.7M | $18.9M | $19.8M | $16.8M | $13.6M | $11.4M |
| Operating margin | 41.2% | 45.9% | 44.5% | 37.6% | 32.5% | 38.5% | 37.9% | 33.4% | 33.2% | 29.6% |
| Net income | $12.1M | $8.51M | $18.6M | $14.7M | $10.8M | $14.8M | $16.5M | $16.6M | $13.9M | $11.3M |
| Net margin | 30.9% | 20.5% | 44.2% | 31.4% | 25.6% | 30.1% | 31.5% | 33.1% | 33.9% | 29.3% |
| EPS (diluted) | $3.22 | $2.28 | $4.95 | $3.94 | $2.94 | $4.04 | $4.52 | $4.57 | $3.96 | $3.48 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $14.5M | $16.9M | $16.8M | $17.1M | $20.1M | $21.2M | $21.1M | $22.3M | $14.8M | $14.7M |
| Capital expenditures | $3.29M | $1.60M | $402K | $540K | $860K | $552K | $809K | $639K | $230K | $371K |
| Free cash flow | $11.2M | $15.3M | $16.4M | $16.5M | $19.3M | $20.7M | $20.3M | $21.6M | $14.6M | $14.3M |
| Share buybacks | — | $0.00 | $1.21M | $398K | $6.98M | $0.00 | $2.50M | $0.00 | $20.0M | $8.36M |
| Dividends paid | $3.92M | $2.96M | $4.03M | $4.11M | $4.12M | $11.5M | $3.16M | $4.28M | $4.26M | $3.98M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $26.3M | $39.9M | $51.1M | $42.8M | $51.6M | $61.0M | $75.1M | $92.9M | $83.0M | $85.8M |
| Total assets | $76.2M | $92.7M | $99.8M | $110M | $112M | $116M | $124M | $135M | $123M | $123M |
| Total liabilities | $6.95M | $14.6M | $10.8M | $8.69M | $8.92M | $8.50M | $9.62M | $7.14M | $5.11M | $3.27M |
| Long-term debt | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shareholders' equity | $69.2M | $78.1M | $89.0M | $101M | $103M | $107M | $114M | $128M | $117M | $119M |
| Retained earnings | $81.1M | $85.6M | $100M | $111M | $111M | $115M | $126M | $138M | $129M | $129M |
| Shares (wtd avg diluted) | 3.77M | 3.74M | 3.75M | 3.74M | 3.67M | 3.66M | 3.64M | 3.64M | 3.50M | 3.24M |
Every figure is extracted from UTAH MEDICAL PRODUCTS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.